A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

被引:93
|
作者
Li, Huafang [2 ]
Rui, Qing [1 ]
Ning, Xiaoping [3 ]
Xu, Haiyan [3 ]
Gu, Niufan [2 ]
机构
[1] Xian Janssen Pharmaceut Ltd, CNS, Med Affairs, Beijing 100025, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
Long-acting injectable; Paliperidone palmitate; PANSS; Risperidone; Schizophrenia; SAFETY; EFFICACY; SCALE;
D O I
10.1016/j.pnpbp.2011.02.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia. Eligible Chinese adults (N = 452) with schizophrenia were randomized (1:1) to either PP (N = 229; deltoid injections on day 1 [150 mg eq.] and day 8 [100 mg eq.]; then once-monthly deltoid or gluteal injections, flexibly dosed [50, 100, or 150 mg eq.]). or RIS-LAI (N = 223; once-biweekly gluteal injections, flexibly dosed [25, 37.5 or 50 mg]). RIS-LAI-treated patients received oral risperidone supplementation (1-6 mg/day) at initiation and with RIS-LAI dose increases. Mean (SD) Positive and Negative Syndrome Scale (PANSS) total score at baseline was 83.2 (12.44). Mean (SD) change from baseline to endpoint in PANSS total scores (primary efficacy measure) was: -23.6 (16.28) for PP group and -26.9 (15.43) for RIS-LAI group. PP was noninferior to RIS-LAI (least squares mean difference [95% CI]: -2.3 [-5.20; 0.63]; predetermined non-inferiority margin: -5.5). Mean (SD) change from baseline to endpoint in Clinical Global Impression-Severity scale score was: -1.5 (1.24; PP group), -1.7 (1.16; RIS-LAI group) and in Personal and Social Performance Scale scores was: 16.8 (14.76; PP group), 18.6 (13.92; RIS-LAI group). The incidence of treatment-emergent adverse events (TEAEs) was similar between the two groups (73% [PP]; 75% [RIS-LAI]). The most common TEAEs were akathisia, tremor, and insomnia. The study demonstrated the noninferiority of PP (50-150 mg eq., flexibly dosed, without oral paliperidone supplementation) to risperidone-LAI (25-50 mg, flexibly dosed, with oral risperidone supplementation) for the treatment of acute schizophrenia in adult Chinese patients. PP injections were generally tolerable, and no new safety signals were detected in this population. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1002 / 1008
页数:7
相关论文
共 50 条
  • [21] Alternative initiation regimen of paliperidone palmitate long-acting injectable
    Menendez Gil, I. E.
    Romero Guillena, S. L.
    Plasencia Garcia De Diego, B. O.
    EUROPEAN PSYCHIATRY, 2022, 65 : S284 - S285
  • [22] Long-acting injectable risperidone for the treatment of schizophrenia
    Moeller, Hans-Juergen
    DRUGS, 2007, 67 (11) : 1541 - 1566
  • [23] Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain
    Javier Quintero
    Itziar Oyagüez
    Beatriz González
    Ignacio Cuervo-Arango
    Ignacio García
    Miguel Angel Casado
    Clinical Drug Investigation, 2016, 36 : 479 - 490
  • [24] Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain
    Quintero, Javier
    Oyaguez, Itziar
    Gonzalez, Beatriz
    Cuervo-Arango, Ignacio
    Garcia, Ignacio
    Angel Casado, Miguel
    CLINICAL DRUG INVESTIGATION, 2016, 36 (06) : 479 - 490
  • [25] A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
    Henry A Nasrallah
    Srihari Gopal
    Cristiana Gassmann-Mayer
    Jorge A Quiroz
    Pilar Lim
    Mariëlle Eerdekens
    Eric Yuen
    David Hough
    Neuropsychopharmacology, 2010, 35 : 2072 - 2082
  • [26] A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
    Nasrallah, Henry A.
    Gopal, Srihari
    Gassmann-Mayer, Cristiana
    Quiroz, Jorge A.
    Lim, Pilar
    Eerdekens, Marielle
    Yuen, Eric
    Hough, David
    NEUROPSYCHOPHARMACOLOGY, 2010, 35 (10) : 2072 - 2082
  • [27] Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia
    Alphs, Larry
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Ma, Yi-Wen
    Sliwa, Jennifer Kern
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1029 - 1042
  • [28] FLEXIBLY DOSED PALIPERIDONE PALMITATE IN NON-ACUTE BUT SYMPTOMATIC PATIENTS WITH SCHIZOPHRENIA PREVIOUSLY UNSUCCESSFULLY TREATED WITH LONG-ACTING INJECTABLE RISPERIDONE
    Schreiner, Andreas
    Bergmans, Paul
    Llorca, Pierre-Michel
    Corrivetti, Giulio
    Cosar, Behcet
    Cherubin, Pierre
    Hargarter, Ludger
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S363 - S363
  • [29] FLEXIBLY DOSED PALIPERIDONE PALMITATE IN NON-ACUTE BUT SYMPTOMATIC PATIENTS WITH SCHIZOPHRENIA PREVIOUSLY UNSUCCESSFULLY TREATED WITH LONG-ACTING INJECTABLE RISPERIDONE
    Schreiner, A.
    Bergmans, P.
    Llorca, P. M.
    Corrivetti, G.
    Cosar, B.
    Cherubin, P.
    Hargarter, L.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [30] FLEXIBLY DOSED PALIPERIDONE PALMITATE IN NON-ACUTE BUT SYMPTOMATIC PATIENTS WITH SCHIZOPHRENIA PREVIOUSLY UNSUCCESSFULLY TREATED WITH LONG-ACTING INJECTABLE RISPERIDONE
    Schreiner, A.
    Bergmans, P.
    Llorca, P-M
    Corrivetti, G.
    Cosar, B.
    Cherubin, P.
    Hargarter, L.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2014, 48 : 130 - 131